Vertex Pharmaceuticals said Wednesday it will stop working on a closely watched experimental drug because of safety signals seen in a mid-stage study.
The study was testing Vertex's drug, VX-814, in patients with an inherited disorder that leaves them with too little of a lung-protecting protein called alpha-1 antitrypsin, or AAT.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,